vs
Metallus Inc.（MTUS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Metallus Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$267.3M vs $207.3M），Metallus Inc.净利率更高（-5.3% vs -62.0%，领先56.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.1%），Metallus Inc.自由现金流更多（$-37.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -8.8%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
MTUS vs RARE — 直观对比
营收规模更大
MTUS
是对方的1.3倍
$207.3M
营收增速更快
RARE
高出14.7%
11.1%
净利率更高
MTUS
高出56.7%
-62.0%
自由现金流更多
MTUS
多$63.6M
$-100.8M
两年增速更快
RARE
近两年复合增速
-8.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $207.3M |
| 净利润 | $-14.3M | $-128.6M |
| 毛利率 | 2.2% | — |
| 营业利润率 | -7.7% | -54.7% |
| 净利率 | -5.3% | -62.0% |
| 营收同比 | 11.1% | 25.9% |
| 净利润同比 | 33.2% | 3.5% |
| 每股收益（稀释后） | $-0.34 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MTUSRARE
| Q4 25 | $267.3M | $207.3M | ||
| Q3 25 | $305.9M | $159.9M | ||
| Q2 25 | $304.6M | $166.5M | ||
| Q1 25 | $280.5M | $139.3M | ||
| Q4 24 | $240.5M | $164.6M | ||
| Q3 24 | $227.2M | $139.5M | ||
| Q2 24 | $294.7M | $147.0M | ||
| Q1 24 | $321.6M | $108.8M |
净利润MTUSRARE
| Q4 25 | $-14.3M | $-128.6M | ||
| Q3 25 | $8.1M | $-180.4M | ||
| Q2 25 | $3.7M | $-115.0M | ||
| Q1 25 | $1.3M | $-151.1M | ||
| Q4 24 | $-21.4M | $-133.2M | ||
| Q3 24 | $-5.9M | $-133.5M | ||
| Q2 24 | $4.6M | $-131.6M | ||
| Q1 24 | $24.0M | $-170.7M |
毛利率MTUSRARE
| Q4 25 | 2.2% | — | ||
| Q3 25 | 11.4% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 5.3% | — | ||
| Q2 24 | 8.2% | — | ||
| Q1 24 | 15.7% | — |
营业利润率MTUSRARE
| Q4 25 | -7.7% | -54.7% | ||
| Q3 25 | 3.6% | -106.9% | ||
| Q2 25 | 2.8% | -64.8% | ||
| Q1 25 | 1.0% | -102.6% | ||
| Q4 24 | -10.1% | -74.3% | ||
| Q3 24 | -3.1% | -94.6% | ||
| Q2 24 | 2.1% | -79.1% | ||
| Q1 24 | 9.3% | -151.9% |
净利率MTUSRARE
| Q4 25 | -5.3% | -62.0% | ||
| Q3 25 | 2.6% | -112.8% | ||
| Q2 25 | 1.2% | -69.0% | ||
| Q1 25 | 0.5% | -108.5% | ||
| Q4 24 | -8.9% | -80.9% | ||
| Q3 24 | -2.6% | -95.7% | ||
| Q2 24 | 1.6% | -89.5% | ||
| Q1 24 | 7.5% | -156.8% |
每股收益（稀释后）MTUSRARE
| Q4 25 | $-0.34 | $-1.28 | ||
| Q3 25 | $0.19 | $-1.81 | ||
| Q2 25 | $0.09 | $-1.17 | ||
| Q1 25 | $0.03 | $-1.57 | ||
| Q4 24 | $-0.46 | $-1.34 | ||
| Q3 24 | $-0.13 | $-1.40 | ||
| Q2 24 | $0.10 | $-1.52 | ||
| Q1 24 | $0.52 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $156.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $686.0M | $-80.0M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MTUSRARE
| Q4 25 | $156.7M | $421.0M | ||
| Q3 25 | $191.5M | $202.5M | ||
| Q2 25 | $190.8M | $176.3M | ||
| Q1 25 | $180.3M | $127.1M | ||
| Q4 24 | $240.7M | $174.0M | ||
| Q3 24 | $254.6M | $150.6M | ||
| Q2 24 | $272.8M | $480.7M | ||
| Q1 24 | $278.1M | $112.3M |
总债务MTUSRARE
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $5.4M | — | ||
| Q3 24 | $13.2M | — | ||
| Q2 24 | $13.2M | — | ||
| Q1 24 | $13.2M | — |
股东权益MTUSRARE
| Q4 25 | $686.0M | $-80.0M | ||
| Q3 25 | $697.7M | $9.2M | ||
| Q2 25 | $690.0M | $151.3M | ||
| Q1 25 | $686.1M | $144.2M | ||
| Q4 24 | $690.5M | $255.0M | ||
| Q3 24 | $712.7M | $346.8M | ||
| Q2 24 | $736.3M | $432.4M | ||
| Q1 24 | $739.3M | $140.3M |
总资产MTUSRARE
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.2B | $1.3B |
负债/权益比MTUSRARE
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-37.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | -13.9% | -48.6% |
| 资本支出强度资本支出/营收 | 13.2% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-93.0M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流MTUSRARE
| Q4 25 | $-1.9M | $-99.8M | ||
| Q3 25 | $22.0M | $-91.4M | ||
| Q2 25 | $34.8M | $-108.3M | ||
| Q1 25 | $-38.9M | $-166.5M | ||
| Q4 24 | $13.9M | $-79.3M | ||
| Q3 24 | $-15.3M | $-67.0M | ||
| Q2 24 | $8.3M | $-77.0M | ||
| Q1 24 | $33.4M | $-190.7M |
自由现金流MTUSRARE
| Q4 25 | $-37.2M | $-100.8M | ||
| Q3 25 | $-6.4M | $-92.7M | ||
| Q2 25 | $17.0M | $-110.7M | ||
| Q1 25 | $-66.4M | $-167.8M | ||
| Q4 24 | $-1.3M | $-79.5M | ||
| Q3 24 | $-32.9M | $-68.6M | ||
| Q2 24 | $-5.8M | $-79.0M | ||
| Q1 24 | $16.0M | $-193.9M |
自由现金流率MTUSRARE
| Q4 25 | -13.9% | -48.6% | ||
| Q3 25 | -2.1% | -58.0% | ||
| Q2 25 | 5.6% | -66.5% | ||
| Q1 25 | -23.7% | -120.5% | ||
| Q4 24 | -0.5% | -48.3% | ||
| Q3 24 | -14.5% | -49.2% | ||
| Q2 24 | -2.0% | -53.7% | ||
| Q1 24 | 5.0% | -178.2% |
资本支出强度MTUSRARE
| Q4 25 | 13.2% | 0.5% | ||
| Q3 25 | 9.3% | 0.8% | ||
| Q2 25 | 5.8% | 1.5% | ||
| Q1 25 | 9.8% | 1.0% | ||
| Q4 24 | 6.3% | 0.1% | ||
| Q3 24 | 7.7% | 1.2% | ||
| Q2 24 | 4.8% | 1.4% | ||
| Q1 24 | 5.4% | 3.0% |
现金转化率MTUSRARE
| Q4 25 | — | — | ||
| Q3 25 | 2.72× | — | ||
| Q2 25 | 9.41× | — | ||
| Q1 25 | -29.92× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.80× | — | ||
| Q1 24 | 1.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MTUS
| Industrial Market Sector | $95.3M | 36% |
| Manufactured Components | $67.8M | 25% |
| Aerospace And Defense | $39.6M | 15% |
| Seamless Mechanical Tubing | $31.3M | 12% |
| Energy Market Sector | $18.3M | 7% |
| Other | $11.3M | 4% |
| Other Market Sector | $3.7M | 1% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
